HT
NRXP icon

Headlands Technologies’s NRX Pharmaceuticals NRXP Stock Holding History

Headlands Technologies’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.9K Buy
+39,394
New +$79.5K 0.01% 674

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Headlands Technologies's NRXP Position: Q1 2026 in Review

Headlands Technologies opened a new position in NRX Pharmaceuticals (NRXP) in Q1 2026: 39,394 shares worth $83.9K. The stake represents 0.01% of the portfolio and ranks #674 among its holdings.

33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • Headlands Technologies held 39,394 shares of NRX Pharmaceuticals worth $83.9K as of Q1 2026.
  • NRX Pharmaceuticals was a new Headlands Technologies position in Q1 2026.
  • NRX Pharmaceuticals made up 0.01% of Headlands Technologies's portfolio in Q1 2026, its #674 holding.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.